Jazz Pharmaceuticals (NASDAQ:JAZZ) CEO Sells $225,370.00 in Stock

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) CEO Renee Gala sold 1,000 shares of the business’s stock in a transaction dated Tuesday, November 3rd. The stock was sold at an average price of $225.37, for a total value of $225,370.00. Following the transaction, the chief executive officer directly owned 140,394 shares of the company’s stock, valued at $31,640,595.78. This represents a 0.71% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jazz Pharmaceuticals Stock Performance

JAZZ opened at $234.76 on Friday. The firm has a market capitalization of $15.07 billion, a P/E ratio of 79.85, a price-to-earnings-growth ratio of 0.44 and a beta of 0.38. The stock’s 50 day moving average price is $229.39 and its two-hundred day moving average price is $217.74. The company has a quick ratio of 1.58, a current ratio of 1.82 and a debt-to-equity ratio of 1.09. Jazz Pharmaceuticals PLC has a 12-month low of $128.80 and a 12-month high of $266.38.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its quarterly earnings results on Monday, November 2nd. The specialty pharmaceutical company reported ($3.88) EPS for the quarter, topping the consensus estimate of ($4.03) by $0.15. Jazz Pharmaceuticals had a return on equity of 16.88% and a net margin of 4.37%. The company had revenue of $1.24 billion for the quarter, compared to the consensus estimate of $1.21 billion. During the same period in the previous year, the business posted $8.13 EPS. The company’s revenue for the quarter was up 10.4% on a year-over-year basis. On average, equities analysts forecast that Jazz Pharmaceuticals PLC will post 11.08 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on JAZZ. Citigroup initiated coverage on shares of Jazz Pharmaceuticals in a research report on Wednesday, September 30th. They set a “buy” rating and a $325.00 target price on the stock. Needham & Company LLC boosted their price target on Jazz Pharmaceuticals from $292.00 to $310.00 and gave the company a “buy” rating in a research note on Wednesday, August 26th. Weiss Ratings lowered shares of Jazz Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Wednesday, October 28th. Robert W. Baird upped their price objective on shares of Jazz Pharmaceuticals from $252.00 to $280.00 and gave the stock an “outperform” rating in a research note on Tuesday, August 4th. Finally, Wall Street Zen lowered shares of Jazz Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday. One analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat, Jazz Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $293.45.

Trending Headlines about Jazz Pharmaceuticals

Here are the key news stories impacting Jazz Pharmaceuticals this week:

• Positive Sentiment: Jazz beat quarterly estimates, reporting $1.24 billion in revenue versus roughly $1.21 billion expected, with revenue up 10.4% year over year. Coverage also reported that the company raised its 2026 revenue outlook to approximately $4.78 billion–$4.85 billion, helping reinforce the growth outlook. Q3 results and outlook
• Positive Sentiment: RBC, Barclays, Morgan Stanley and JPMorgan issued favorable commentary or raised price targets after the results. The analyst optimism adds support to the stock’s post-earnings momentum. Barclays price-target update
• Neutral Sentiment: CEO Renée Galá sold 1,000 shares under a pre-arranged Rule 10b5-1 plan and retained 140,394 shares. Director Bruce Cozadd also sold 6,000 shares under a pre-arranged plan, while CAO Patricia Carr sold 1,413 shares and retained 6,512. These sales may draw investor attention, but planned transactions are not necessarily a signal about near-term business prospects. Insider transaction coverage

Institutional Investors Weigh In On Jazz Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the stock. USA Financial Formulas bought a new position in shares of Jazz Pharmaceuticals during the first quarter worth about $25,000. Pension & Wealth Management Advisors Inc. bought a new position in Jazz Pharmaceuticals during the third quarter worth $32,000. Ameritas Advisory Services LLC bought a new stake in shares of Jazz Pharmaceuticals during the 2nd quarter worth about $47,000. Thurston Springer Miller Herd & Titak Inc. acquired a new stake in Jazz Pharmaceuticals during the second quarter worth approximately $61,000. Finally, Elevation Wealth Partners LLC boosted its holdings in shares of Jazz Pharmaceuticals by 156.4% during the third quarter. Elevation Wealth Partners LLC now owns 259 shares of the specialty pharmaceutical company’s stock worth $60,000 after acquiring an additional 158 shares during the period. 89.14% of the stock is owned by institutional investors.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing medicines for serious diseases, particularly in neuroscience and oncology. Founded in 2003, the company is headquartered in Dublin, Ireland, and serves patients in the United States and international markets.

Its products include treatments for sleep disorders and seizure conditions, such as Xywav, Xyrem, Sunosi and Epidiolex. Jazz also offers medicines used in cancer care, including Zepzelca, Vyxeos and Rylaze, as well as Defitelio for a serious complication following stem cell transplantation.

Jazz expanded its portfolio through acquisitions, including the 2021 acquisition of GW Pharmaceuticals, which added Epidiolex and other cannabinoid-based medicines.